Inactive Instrument

Other languages Forma Therapeutics Holdings, Inc.

Equities

FMTX

US34633R1041

Other languages

Unlock all the news: Be the first to know and act before the market!

Novo Nordisk announces the completion of the Forma Therapeutics acquisition	22-10-17
Sector Update: Health Care Stocks Ending with Modest Declines	22-10-14
Sector Update: Health Care Stocks Sliding with Broader Friday Markets	22-10-14
Novo Nordisk Completes Acquisition of Forma Therapeutics; Forma Shares to be Delisted	22-10-14
Novo Nordisk Completes Acquisition of Forma Therapeutics	22-10-14
FORMA THERAPEUTICS HOLDINGS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	22-10-14
Forma Therapeutics Holdings, Inc. Announces Board Changes	22-10-14
Forma Therapeutics Holdings, Inc.(NasdaqGM:FMTX) dropped from NASDAQ Composite Index	22-10-14
Forma Therapeutics Holdings, Inc.(NasdaqGM:FMTX) dropped from S&P Global BMI Index	22-10-14
Forma Therapeutics Holdings, Inc.(NasdaqGM:FMTX) dropped from S&P TMI Index	22-10-14
Forma Therapeutics Holdings, Inc.(NasdaqGM:FMTX) dropped from NASDAQ Biotechnology Index	22-10-13
Novo Nordisk A/S (CPSE:NOVO B) completed the acquisition of Forma Therapeutics Holdings, Inc. (NasdaqGM : FMTX) from RA Capital Management, L.P. and others.	22-10-12
Sickle Cell Disease Association of America & Partners Launch New PSA to Boost Awareness and Understanding of the Disease	22-09-30
FORMA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forma Therapeutics, Holdings Inc. - FMTX	22-09-27
Forma Therapeutics : Amendment to Initial Statement of Beneficial Ownership - Form 3/A	22-09-19
FORMA THERAPEUTICS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forma Therapeutics, Holdings Inc. - FMTX	22-09-02
Credit Suisse Downgrades Forma Therapeutics Holdings to Neutral from Outperform Following News of Novo Nordisk Acquisition, Lowers Price Target to $20 from $33	22-09-02
HC Wainwright Downgrades Forma Therapeutics Holdings to Neutral From Buy, Adjusts Price Target to $20 From $53	22-09-02
Jefferies Downgrades Forma Therapeutics Holdings to Hold From Buy, Adjusts Price Target to $20 From $28	22-09-02
Nvidia, Hormel fall; Nutanix, Forma Therapeutics rise	22-09-01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Forma Therapeutics Holdings, Inc.

Equities

FMTX

US34633R1041

Other languages

Filters